Research Roundup


Debbie Rigby presents the latest research news relevant to pharmacy

Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease

Evidence from a total of 11 trials involving more than 118,000 patients highlights the importance of balancing the benefit of ASCVD reduction with the risk of bleeding from low-dose aspirin for primary prevention. This is facilitated by a free and readily-available evidence-based clinical decision support tool (app).

JAMA Intern Med. Published online June 20, 2016.

Viewpoint

 

Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate

A Danish population study (n= 61 990) examined the long-term safety and efficacy of alendronate in men and women with osteoporosis. These findings support an acceptable balance between benefit and risk with treatment with alendronate in terms of fracture outcomes, even for over 10 years of continuous use. The rate of fracture of the subtrochanteric femur or femoral shaft or the hip was 3.4 per 1000 person years

BMJ 2016;353:i3365.

 

Pharmacists’ interventions on clinical asthma outcomes: a systematic review

A systematic review of 21 studies has confirmed that pharmacists’ interventions for asthma have a positive impact on the percentage of controlled patients, Asthma Control Questionnaire (ACQ) scores, severity and symptoms.

Eur Respir J 2016;47:1043-6.

 

Adjunctive Nutraceuticals for Depression

A systematic review of 40 controlled clinical trials has concluded that folic acid and related substances, S-adenosylmethionine [SAMe], and vitamins B6 and B12, various forms of tryptophan, and omega-3 fatty acids added to conventional antidepressants are effective for treating depressive disorders.

Am J Psychiatry. 2016;173(6):575-87.

Medscape commentary

 

 

Previous Pharmacists lack confidence in supplying naloxone
Next DAAs: Taking the right dose?

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.